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Aim: TAp73 is a tumor suppressor, which compensates for p53 loss and induces apoptosis in tumors in
response to genotoxic stress or small-molecule treatments. Pancreatic ductal adenocarcinoma has a late
onset of the disease, responds poorly to the existing therapies and has a very low survival rates. Result:
Here, using drug-repurposing approach, we found that protoporphyrin IX (PpIX) and benzoporphyrin
derivative (BPD) monoacid ring A activate TAp73 and induce apoptosis in pancreatic cancer cells. PpIX and
BPD induce reactive oxygen species and inhibit thioredoxin reductase 1. Conclusion: Thus, PpIX and BPD
target cancer cells’ vulnerabilities namely activate TAp73 tumor suppressor and inhibit oncogenic Trx1.




















Two pathways leading to the induction of potent apoptosis by protoporphyrin IX and Verteporfin in
mutant TP53 pancreatic cancer cells. One pathway is through inhibition of TAp73/MDM2 interactions and
induction of TAp73-related apoptosis and the second pathway converges on inhibition of oncogenic TrxR
and accumulation of reactive oxygen species.
Lay abstract: Despite all efforts, pancreatic cancer remains one of the most aggressive tumors. Late di-
agnoses, often linked with the asymptomatic disease progression, make pancreatic cancer extremely dif-
ficult to treat. We have assessed drugs that are already clinically used in the photodynamic therapy of
actinic keratosis and age-related macular degeneration and showed that the compounds induce
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apoptotic death of cancer cells. The mechanism is via activation of the p73 tumor suppressor and inhi-
bition of the oncogenic thioredoxin reductase. Molecules with a complementary mechanism of action
inducing cell death might be very promising candidates for improved cancer therapy in pancreatic cancer
patients.
First draft submitted: 3 September 2018; Accepted for publication: 3 December 2018; Published online:
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Pancreatic cancer is among the most lethal human cancer types and the fifth leading cause of cancer-related deaths
worldwide [1]. In Europe, the death rates from pancreatic cancer continue to increase and the median survival rate
for patients diagnosed with metastatic disease is only 4.6 months. Pancreatic cancer is predicted to become the
second cause of cancer-related deaths in 2020 [2,3].
To date, it is still one of the most challenging solid tumors to treat. Most of the patients die within 1 year after
diagnosis and only about 5% survive up to 5 years in the USA. This is mainly due to the late onset of the disease,
high incidence of the metastatic stage and lack of effective treatments [4].
Treatment of pancreatic cancer is difficult and depends on the stage of the disease at the time of diagnosis. The
response to currently available therapies is disappointing and the poor outcome is likely stemming from a complex
set of several factors described below.
In patients not suitable for the resection with the curative intent, palliative chemotherapy may be used to improve
the quality of life. Gemcitabine (GEM) was approved by the US FDA in 1998 for the treatment of patients with
advanced pancreatic cancer and remains the main first-line therapy for pancreatic cancer patients, regardless of
primary and acquired resistance. This resistance is partially due to DNA-repair polymorphism [5], mutations in
the p53 pathway [6] or the existence of cancer stem cells [7]. Recently, combination treatment regimens with 5-
fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) brought some promise in overcoming treatment resistance
in patients with metastatic disease. However, pancreatic cancer remains a major unmet medical need. Thus, there
is an urgent need to develop more effective treatments [8].
Pancreatic cancer is one of the cancer types in which mutant p53 impacts disease progression. TP 53 is mutated
in 75% of cases of pancreatic carcinomas [9]. TP 53 gene mutations co-exist with activating mutations in classical
oncogenes including K-Ras, which accounts for 75–90% of all pancreatic cancer cases [10].
TP 53 mutations result with the loss of p53 tumor suppressor function and preferentially promote the so-called
gain of new functions. As evidenced, mutant p53 is the main driver of disease progression in pancreatic cancers.
Selective therapies aiming at restoring p53 pathway to overcome the p53 loss in cancer cells, but not in normal
cells, appear to be an attractive strategy for diseases such as chemotherapy-resistant pancreatic cancer. Despite the
ongoing efforts, small molecules re-activating mutant p53 are still in clinical development [11].
It has been previously shown that photodynamic therapy (PDT) of cancer, which uses photoactivatable com-
pounds and light to target cancer cells, is effective against numerous pancreatic cancer cell lines as monotherapy [12]
or in combination with GEM [13] or irinotecan [14].
The majority of the clinically approved compounds used for PDT are porphyrins and their derivatives [14].
Protoporphyrin IX (PpIX) is a metabolite of γ-aminolevulinic acid, a pro-drug applied in PDT of cancer [14]. PpIX
itself, without light excitation, was shown to induce wild-type (wt) p53-related cell death in several human cancer
cell lines including human colon carcinoma [15]. Interestingly, it has recently been demonstrated that PpIX stabilizes
and activates TAp73 and induces TAp73-dependent apoptosis in cancer cells lacking TP 53 [16].
TrxR1 is a selenoprotein of the thioredoxin system and is central in maintaining redox homeostasis in cells [17].
TrxR has a protective role against oxidative stress and contributes to tumor progression once the disease has already
developed. Thus, TXNRD 1 is often overexpressed in cancers and is a promising target for improved cancer
therapy [17].
Here, we found that PpIX and benzoporphyrin derivative (BPD; verteporfin) induce TAp73 and its pro-apoptotic
targets on mRNA and protein levels. Next, it was demonstrated that PpIX and BPD induce reactive oxygen species
(ROS) and antioxidant response genes HMO X-1 and NQ O1. PpIX and BPD inhibited TrxR1 in vitro and in
pancreatic cancer cells harboring mutant p53. Taken together, our data add up to the mechanism by which PpIX
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and now BPD induce apoptosis in cancer cells harboring TP 53 gene mutations, which is via reactivation of TAp73
tumor suppressor and inhibition of TrxR1.
Materials & methods
Cell culture
Human pancreatic cancer cell lines, Paca3 (wt TP53), MiaPaca2 (mutant TP53R248W) and Panc1 (mutant
TP53R273H) were kindly provided by Dr Rainer Heuchel from Karolinska Institutet, Sweden. Mouse pancreatic
ductal cancer cell line Panc02 (wt TP53) was provided by Dr Maximilian Schnurr from University of Munich,
Germany and made available by Dr Yihai Cao from Karolinska Institutet, Sweden.
Normal human pancreatic ductal epithelial cells (HPDE) immortalized by HPV transformation [18] were also
provided by Dr Heuchel. Cells were maintained in DMEM medium supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin solution (Sigma-Aldrich, Munich, Germany). The cells were cultured at 37◦C in a
humidified incubator with 5% CO2. The cells were routinely checked for mycoplasma during the whole duration
of the project.
Chemicals
PpIX and BPD were purchased from Sigma-Aldrich dissolved in 100% DMSO (Sigma-Aldrich) to a final concen-
tration of 2 mg/ml and stored in dark in amber tubes at room temperature (PpIX) or at -20◦C (BPD) until further
use.
Cisplatin (cis-diamminedichloridoplatinum(II), CDDP; Sigma-Aldrich) was dissolved in 0.9% NaCl to a con-
centration of 25 mM and used at final concentration of 20 μM. GEM (2′,2′-difluoro-2′-deoxycytidine, GEM;
Abcam, Cambridge, UK) was prepared as 1 mM stock solution in 0.9% NaCl. Resveratrol (Enzo Biochem, NY,
USA) was reconstituted to 40 mM in 100% DMSO, aliquoted and stored at −20◦C.
MTT reagent (Sigma-Aldrich) was reconstituted in PBS (prepared from 1× tablets Sigma-Aldrich) to 5 mg/ml,
filter-sterilized and stored at +4◦C for a week or at -20◦C until further use.
Verteporfin uptake & cellular localization
Cells were incubated with 2.5 μg/ml of PpIX or BPD reconstituted in cell culture media for 3 h, washed
three times with PBS and co-stained with ER-Tracker™ Green for live-cell imaging (Molecular Probes, OR, USA)
according tomanufacturer protocol. 4′,6-diamidino-2-phenylindole (DAPI;Molecular Probes) was used for nuclear
counterstaining. An organelle marker was excited using a 488 nm laser and BPDwas excited with 420 nm (emission
at 690 nm). Images were taken using an Olympus IX-71 microscope and DeltaVision SoftWoRx.
Cell viability
Cell viability was assessed by MTT assay as provided by the manufacturer (Sigma-Aldrich) and as described
previously [15]. Briefly, 3000 cells were seeded in 96-well plate and allowed to adhere overnight. The cells were
treated with the increasing concentrations of the compounds (PpIX or BPD) or 25 or 5 μM cisplatin or GEM for
72 h and the viability was measured using MTT reagent according to the manufacturer protocol.
Real-time PCR
Quantitative PCR was performed as described previously [19]. Cells were seeded in 6-well plates, allowed to
adhere for 24 h and treated with 2.5 μg/ml PpIX or BPD for 8 h. After isolation, mRNA was reverse
transcribed to cDNA according to the manufacturer’s instructions (Bio-Rad, Solna, Sweden). For qPCR re-
action 150 nM, 10 ng cDNA, 7.5 μl 2 × master mix (Bio-Rad) and water to a total of 15 μl were used.
Primers used: GAPDH forward: TCATTTCCTGGTATGACAACG and reverse: ATGTGGGCCATGAGGT,
NOXA forward 5′-AAGTGCAAGTAGCTGGAAG-3′, reverse: 5′-TGTCTCCAAATCTCCTGAGT-3′, PUMA
forward: 5′-CTCAACGCACAGTACGAG-3′ and reverse: 5′-GTCCCATGAGATTGTACAG-3′, HMOX-1 for-
ward: 5′-TTCACCTTCCCCAACATTGC-3′ and reverse: 5′-TATCACCCTCTGCCTGACTG-3′, Bid forward:
5′-GTGAGGTCAACAACGGTTCC-3′ and reverse: 5′-TGCCTCTATTCTTCCCAAGC-3′, Bim forward: 5′-
TGGCAAAGCAACCTTCTGATG-3′ and reverse: 5′-GCAGGCTGCAATTGTCTACCT-3′, Bax forward: 5′ –
GCTGTTGGGCTGGATCCAAG – 3′ and reverse: 5′ – TCAGCCCATCTTCTTCCAGA – 3′.
future science group www.future-science.com
Research Article Acedo, Fernandes & Zawacka-Pankau
Thioredoxin reductase activity assay
For the enzymatic activity of purified TrxR1 we followed the protocol previously described [20,21]. Briefly, 10 nM
of purified TrxR1 [22] was pre-incubated with BPD at the indicated concentrations (0–20 μM) in 50 μl phosphate
EDTA (PE) buffer supplemented with 150 μM NADPH for 30 min at room temperature. Next, 2.5 mM DTNB
and 150 μM NADPH were added to the samples just before measurement. DTNB reduction was performed for
6 min by detection of TNB anion formation detected as a change in the absorbance at 412 nm.
For cellular TrxR activity, Panc1 and MiaPaCa2 cells were treated with 2.5 μg/ml PpIX or BPD for 6 h, after
which they were harvested and resuspended in a Tris-EDTA (TE) buffer containing a protease inhibitor cocktail
(complete, mini protease cocktail tablets, Roche, Solna, Sweden). Cells were sonicated and the total protein
concentration of the supernatant was determined using a Bradford reagent kit (Bio-Rad Laboratories, Solna,
Sweden). Cellular TrxR1 activity was determined using the previously described endpoint Trx-dependent insulin
reduction assay [20]. Briefly, total cellular protein (20 μg) was incubated with 15 μM recombinant human wt Trx in
the presence of 297 μM insulin, 1.3 mM NADPH, 85 mMHepes buffer (pH 7.6) and 13 mM EDTA for 30 min
at 37◦C, in a total volume of 50 μl. The reaction was stopped by the addition of 200 μl of 7.2 M guanidine–HCl
in 0.2 M Tris–HCl (pH 8.0) containing 1 mMDTNB. The activity was then determined by measuring absorbance
at 412 nm using a VersaMax microplate reader (Molecular Devices, CA, USA) with a background absorbance
reference for each sample, containing all components except purified TrxR, incubated and treated in the same
manner.
Cell death detection
Propidum iodide (PI) and FITC-Annexin V (from BD Biosciences, CA, USA) staining was performed according
to the manufacturer’s protocols and FACS analysis was carried out using the CELLQuest software (CELLQuest,
NJ, USA) as described previously [23].
ROS measurement
Cells were treaded with compounds for 16 h, washed with PBS and then the generation of ROS assessed by flow
cytometry. ROS were detected using 2′,7′-dichlorofluorescein (H2DCF; Sigma-Aldrich) and method described
previously [21].
Hydroethidine staining was performed according to the manufacturer protocol (Life Technologies, Stock-
holm, Sweden). Data analysis was performed with the CELLQuest software (CELLQuest, BD Biosciences, Franklin
Lakes, NJ, USA).
Western blotting
Western blotting was performed according to the standard protocol. Briefly, 100 μg of total cell lysate was
subjected to electrophoresis, after transfer the following antibodies were used to detect proteins: anti-TAp73
(A300-126A) (Bethyl Laboratories, TX, USA), anti-BAX (N-20; Santa Cruz Biotechnology, Germany) anti-
PUMA (ABC158; Merck, MA, USA), anti-HO-1 (H-105; Santa Cruz Biotechnology), anti-NRF2 (H-300; Santa
Cruz Biotechnology), anti-Bid (FL-195; Santa Cruz Biotechnology, TX, USA), anti-PARP (F-2; Santa Cruz
Biotechnology), anti-β-actin (A2228; Sigma-Aldrich).
Results
BPD localize into the cytoplasm of Panc1 cancer cells
Pancreatic ductal adenocarcinomas (PDACs) are cancers of poor clinical outcome due to the development of
chemoresistance and disease relapse with mutant p53 being associated with the aggressiveness of the disease.
Whether the re-activation of TAp73 can compensate for the p53 loss in cancers with the TP 53 gain-of-function
mutations has not been unequivocally demonstrated yet. Therefore, we tested the outcome of TAp73 activation in
PDAC cancer cell lines harboring hot-spot TP 53 R273H mutation.
First, we assessed the subcellular localization of BPD in Panc1 mutant TP53R273H-expressing cancer cells
(Figure 1A). Fluorescence microscopy indicated that BPD (red fluorescence emission) is uptaken to high degree by
cancer cells 3 h after incubation with the drug. Next, we found that verteporfin localized in large in cytoplasm and
partially in the endoplasmic reticulum. This is in agreement with the previously published data.
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Figure 1. Benzoporphyrin derivative accumulates in cancer cells and inhibits proliferation in a dose-dependent manner. (A)
Fluorescence microscopy shows that benzoporphyrin derivative (BPD) accumulates largely in the cytoplasm and partially in endoplasmic
reticulum in Panc1 pancreatic cancer cells. Nuclei were stained with DAPI and mitochondria and endoplasmic reticulum with ER-Tracker
Green, respectively. The image is a representative data of three independent experiments. (B) PpIX (orange bars) and BPD (red bars)
inhibit proliferation of PaCa3 (wtTP 53), Panc1 (mtTP53R273H) (C) and Panc02 (D) pancreatic cancer cells as assessed by MTT assay. Cells
were treated for 72 h, 25 μM cisplatin (CDDP, green bars) and 5 μM gemcitabine (GEM, blue bars) were used as positive controls of
growth inhibition. (E) PpIX (orange bars) and BPD (red bars) do not inhibit proliferation of normal, nontransformed ductal epithelial
(HPDE) cells as assessed by MTT assay.
PpIX: Protoporphyrin IX.
PpIX & BPD inhibit proliferation of pancreatic cancer cells but not of nontransformed human
ductal epithelial cells
To assess the impact of PpIX and BPD on the proliferation of pancreatic cancer cells we performed MTT viability
assay. The standard treatment for the advanced pancreatic cancer includes monotherapy with GEM. Therefore, we
used GEM in the most of the experiments for the comparative purposes.
MTT showed that PpIX andBPD inhibit cancer cells’ proliferation in a dose-dependent fashion (Figure 1B–E). In
agreement with the previous data, cancer cells expressing wt p53 protein (PaCa3) were sensitive to 72 h-treatment
with PpIX [15] (Figure 1B) and showed even higher growth inhibition rate after BPD treatment. Interestingly,
mutant p53-harboring cells (Panc1) were more sensitive to PpIX than wtp53-expressing PaCa3 cells and slightly
less sensitive to BPD (Figure 1C).
The calculated IC50 value for PpIXwas 4.4μMfor PaCa3 (wtTP53) cells and 3.5μMfor Panc1 (mtTP53R273H)
and 2.2 and 2.8 μM for BPD, respectively.
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Of note, murine (Panc02) and human (MiaPaca2) pancreatic cancer cells were less sensitive to PpIX and BPD at
the concentrations tested (Figure 1D and data not shown) and normal human epithelial ductal cells were insensitive
(Figure 1E). On the other hand, all cell lines applied in the study were highly susceptible to low dose (25 μM)
cisplatin and 5 μM GEM.
Consistent with the previous data, wtp53 cancer cells were sensitive to PpIX [15]. Interestingly, mutant p53 Panc1
cancer cells were the most sensitive among the cell lines tested. Based on the above and previous studies, we selected
2.5 μg/ml concentration for further studies on the cell death induction upon reactivation of TAp73 in mutant p53
pancreatic cancer cells.
PpIX & BPD induce apoptosis in PDAC cells
To investigate if the growth inhibition observed in the MTT viability assays was a consequence of the induction of
apoptosis, we treated PaCa3 and Panc1 cells for 48 h with 2.5 μg/ml PpIX or BPD and performed flow cytometry
analysis using PI and Annexin V stainings.We found that Panc1 undergoes high late apoptosis after PpIX treatment,
as demonstrated by above 40% increase of PI positive cells relative to the untreated control. At this time-point,
Annexin V positivity, indicating early apoptosis, increased by 12 or 9% after PpIX or BPD treatments, respectively
(Figure 2C & D). In the PaCa3 cells harboring wtTP53, we observed 10 and 17% increase in PI positive cells after
PpIX or BPD treatment, respectively. The increase in Annexin V-positive cells was 5% for PpIX and 11% for BPD.
Thus, both compounds induce early and late apoptosis in the tested cancer cell lines. Cisplatin, used as a positive
control, induced high early apoptosis in PaCa3 (wtTP53) cells and early and late apoptosis in Panc1 (mtTP53)
cells.
PpIX & BPD induce TAp73 & its pro-apoptotic targets
It has been demonstrated that PpIX reactivates TAp73 tumor suppressor and induces TAp73-dependent apoptosis
in TP 53-null cancer cells [16]. To assess if the growth inhibition observed in pancreatic cancer cells upon treatment
with PpIX and BPD is a result of the ongoing apoptosis, we evaluated the expression of TAp73 tumor suppressor
and its pro-apoptotic targets in PaCa3 and Panc1 cancer cells. Western blotting showed that in the dark, both
PpIX and BPD induce the levels of endogenous TAp73, which correlates with the accumulation of its proapoptotic
targets PUMA, Bax and Bid (Figure 3A–C) in both cell lines. Time-dependent accumulation of the cleaved PARP
was detected in Panc1 cells. Next, in Panc1 cells, PpIX and BPD upregulated the expression of bax, bid, puma
and noxa genes (Figure 3D). This indicates that apoptosis is due to the activation of TAp73 tumor suppressor
(Figure 3A & C). Interestingly, we detected upregulation of the antioxidant response proteins, HO-1 and Nrf2
(Figure 3A–D). PpIX and BPD did not induce PARP cleavage or accumulation of TAp73 and its proapoptotic
targets in nontransformed HPDE cells at the concentrations tested (Figure 3E). We have observed downregulation
of TAp73 after PpIX and BPD treatment; however, the mechanism remains to be elucidated.
PpIX & BPD induce ROS in PDAC
Since we detected accumulation of the antioxidant response proteins after treatment with PpIX and BPD in
pancreatic cancer cells; we thus sought to investigate if PpIX and BPD elevate ROS. We assessed the levels of
ROS using DCFDA and HE probes. Figures 4A–C show that PpIX and BPD induced ROS levels in PaCa3 and
Panc1 cells. Pretreatment with the ROS scavenger resveratrol inhibited the generation of ROS induced by PpIX
and BPD in Panc1 cells (Supplementary Figure 1A). Importantly, the compounds did not induce ROS in HPDE
cells (Supplementary Figure 1B).
PpIX & BPD are inhibitors of thioredoxin reductase
PpIX was first identified as an inhibitor of thioredoxin reductase in an in vitro screen for the inhibitors of the
enzymes [24]. Since we observed significant induction of ROS in cancer cells treatedwith PpIX or BPD and inhibition
of TrxR is known to cause accumulation of ROS, we reasoned that apart from TAp73-dependent apoptosis, PpIX
and BPD inhibit TrxR which might explain the elevated ROS levels detected in the treated cancer cells.
As demonstrated in Figure 5A, recombinant TrxR was inhibited by both, PpIX and BPD. To assess if PpIX and
BPD inhibit TrxR activity in cancer cells also, we treated Panc1 cells with the increasing concentrations of PpIX
or BPD for 6 h and assayed the activity using the end point Trx-dependent insulin-reduction assay. PpIX and
BPD treatment inhibited TrxR1 in Panc1 cancer cells (Figure 5B) as well as in other mutant p53 harboring cell
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Figure 2. Protoporphyrin IX and benzoporphyrin derivative activate early and late apoptosis in pancreatic cancer
cells. (A) Treatment with 2.5 μg/ml PpIX (orange bars) and BPD (red bars) for 48 h induced late (PI staining) and early
apoptosis (FITC-Annexin V) (B) in wtp53-harboring PaCa3 pancreatic cancer cells (n = 3). 20 μM CDDP (green bars) was
used as a positive control for apoptosis induction. (C) Treatment with 2.5 μg/ml PpIX and BPD for 48 h induced late (PI
staining) and early apoptosis (FITC-Annexin V) (D) in mtTP53-harbouring Panc1 pancreatic cancer cells (n = 3). 20 μM
CDDP was used as a positive control for apoptosis induction.
BPD: Benzoporphyrin derivative; PI: Propidum iodide; PpIX: Protoporphyrin IX.
line, MiaPaCa2 (mtTP53R248W). Taken together, these data demonstrate that BPD, similarly to PpIX, is a potent
inhibitor of TrxR in pancreatic cancer cells.
Discussion
Several tyrosine kinases inhibitors were reported to have off-target effects. For example, BRAF inhibitor, vemu-
rafenib, used for treating metastatic melanoma [25] with overall good clinical outcome [26], was manifested to
induce unusual photosensitivity in patients [27]. A recent study by Klaeger et al. [28] showed that several kinase
inhibitors, including vemurafenib, in addition to their designed targets effectively inhibit ferrochelatase, the last
enzyme in the heme biosynthesis. The authors speculated that the accumulation of PpIX, resulting from inhibition
of ferrochelatase might lead to the photosensitivity of the patients upon treatment with kinase inhibitors.
PpIX is a metabolite of γ-aminolevulinic acid, heme precursor and a pro-drug applied in the PDT of cancer [14].
We have shown in a drug-repurposing approach that PpIX re-activates wt p53 and TAp73 tumor suppressors and
induces p53- or TAp73-dependent apoptosis in cancer cells. The mechanism of activation of p53 and TAp73 is
via inhibition of p53/MDM2 and TAp73/MDM2(X) interactions [15,16]. Next, PpIX was identified in the in vitro
screen as a potent, competitive inhibitor of thioredoxin reductase (TrxR) [24]. Thus, here we speculated that PpIX,
exogenously delivered to pancreatic cancer cells harboring TP53 mutations, will induce apoptosis via activation of
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Figure 3. Reactivation of TAp73 by protoporphyrin IX and benzoporphyrin derivative induces apoptosis in
pancreatic cancer cells. (A) Protoporphyrin IX (PpIX) (2.5 μg/ml) induce PARP cleavage in PaCa3 and Panc1 cells and
BPD in Panc1 pancreatic cancer cells (B & C). The effect is time dependent. The accumulation of cleaved PARP
correlates with the stabilization of TAp73 tumor suppressor protein levels and its pro-apoptotic target Bax. Both
compounds upregulated HO-1 and its transcriptional regulator Nrf2. 20 μM CDDP was used as a positive control for
apoptosis induction. (D) Treatment with PpIX (orange bars) and BPD (red bars) increased the mRNA levels of
apoptotic TAp73 targets and the antioxidant response proteins in Panc1 pancreatic cancer cells. (E) PpIX and BPD
treatment did not induce TAp73 or its proapoptotic targets in non-transformed HPDE.
BPD: Benzoporporphyrin derivative; CL: Cleaved; FL: Full length; HPDE: Human pancreatic ductal epithelial cells; HO-1:
Heme oxygenase.




















































































































Figure 4. Protoporphyrin IX and benzoporphyrin derivative induce ROS in pancreatic cancer cells. (A) BPD treatment
upregulates ROS levels in PaCa3 cells as estimated by the 2′,7′-dichlorodihydrofluorescein diacetate staining after 16 h
post-treatment (n = 3). (B–D) Both PpIX and BPD induced ROS in Panc1 cells after 16 h, as assessed by the
2′,7′-dichlorodihydrofluorescein diacetate staining (n = 3).
BPD: Benzoporphyrin derivative; PpIX: Protoporphyrin IX.
the p53 protein family member, TAp73. We also reasoned that PpIX and its clinically applied analog BPD may
simultaneously inhibit TrxR in pancreatic cancer cells.
The detailed analysis revealed that PpIX and BPD, known under the commercial name of Verteporfin, inhibit
proliferation of pancreatic cancer cells without affecting nontransformed cells. The mechanism of growth inhibition
was by the induction of apoptosis. Next, both compounds triggered antioxidant response and induced accumulation
of ROS only in cancer cells but not in normal HPDE cells. The above prompted us to investigate if the robust
induction of ROS is a consequence of the inhibition of TrxR. According to our findings, BPD inhibited the
enzymatic activity of the recombinant thioredoxin reductase. Both PpIX and BPD inhibited the enzyme in Panc1
and MiaPaCa2 cancer cells as demonstrated by the Trx-dependent endpoint insulin reduction assay.
Inhibitors of TrxR are currently under preclinical development and are promising candidates for improved cancer
therapy [29]. Several small molecules activating wt or mutant p53 were also shown to inhibit TrxR [21,30,31]. The
small molecule APR-246, a mutant p53-reactivating compound in Phase II clinical development, is a pro-drug,
converted in cells to methylene quinuclidinone [32]. Methylene quinuclidinone is a Michael acceptor and was
demonstrated to target cysteines in the p53 core domain [33] and selenocysteine (Sec) residues in the C-terminal
motif of TrxR1 [30]. Our findings demonstrate that PpIX and BPD inhibit TrxR. The mechanism by which this
occurs remains to be elucidated. Structural studies on the heme-binding protein, heme oxygenase 2 (HO-2),
revealed that in the oxidized state of cysteine residues in apoprotein, heme binds 2.5-fold more tightly than in the
reduced state [34]. This, together with the finding that the Sec-to-Cys mutant of TrxR1 was resistant to inhibition
by PpIX [24], strongly implies that Sec residue in TrxR might be the binding site of PpIX and BPD (Verteporfin).
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Figure 5. Protoporphyrin IX and benzoporphyrin derivative inhibit thioredoxin reductase activity. (A) BPD (red bars)
inhibits the activity of the recombinant TrxR. The representative data of three independent experiments is presented.
(B) Both PpIX (orange bars) and BPD (red bars) inhibit TrxR in Panc1 and MiaPaCa2 pancreatic cancer cells (n = 2).
BPD: Benzoporphyrin derivative; PpIX: Protoporphyrin IX.
We showed that PpIX and now also BPD activates TAp73 in pancreatic cancer cells, which results in the induction
of apoptotic cell death. In parallel, the compounds induce ROS, which contributes to cell killing. Induction of
ROS levels is with high probability due to the inhibition of TrxR by PpIX and BPD.
Future perspective
Our findings might have an important clinical implication and could support fast repurposing of porphyrins
in treating pancreatic cancer patients harboring TP53 mutations. Dual targeting of TAp73 and TrxR by small
molecules that we have identified might bring therapeutic advantage in overcoming the development of the
treatment-resistant disease. In particular, we foresee that the parallel activation of TAp73 and inhibition of TrxR
will significantly increase the stress burden in already stressed cancer cells when compared with separate approaches,
which will contribute to the selective tumor killing without affecting normal cells.
Supplementary data
See online at: www.future-science.com/doi/full/10.4155/fsoa-2018-0082
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Summary points
• Protoporphyrin IX (PpIX) and benzoporphyrin derivative (BPD) induce apoptosis in pancreatic ductal
adenocarcinoma cells by activating TAp73.
• PpIX and BPD generate reactive oxygen species in pancreatic cancer cells.
• PpIX and BPD inhibit thioredoxin reductase in vitro and in cancer cells.
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